Employer / Commercial Insurance
Covered with requirementsWhat you need to qualify
- Age 18 and older
- BMI of 40 or higher
- BMI of 35 or higher with a weight-related condition (CVD, dyslipidemia, gallstones, gynecological_abnormalities, hypercholesterolemia, HTN, metabolic_syndrome, MAFLD, pulmonary_hypoventilation, OSA, stress_incontinence, T2DM, and weight_bearing_joint_arthropathy)
- BMI of 25 or higher for patients of Asian descent
- 3 months of a documented diet and exercise program
- Prior trial of another GLP-1 medication (Foundayo) for at least 180 days
Qualification pathways
You can qualify through any one of these.
Adult weight loss — Class III obesity
All of:
- Age ≥ 18 years
- BMI ≥ 40 kg/m² (Class III obesity)
- Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
- Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
- Not used in combination with any other GIP and/or GLP-1 receptor agonist
- Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
- Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)
Adult weight loss — Class II obesity with comorbidity
All of:
- Age ≥ 18 years
- BMI 35–39.9 kg/m² (Class II obesity)
- Enrolled in qualified comprehensive weight management program for ≥3 consecutive months
- Documentation of trial and failure of Foundayo (or documented contraindication to Foundayo)
- Not used in combination with any other GIP and/or GLP-1 receptor agonist
- Not used in combination with other weight loss drugs (Rx, OTC, or herbal)
- Coverage criteria apply to Zepbound pens only (vials and Kwikpens are not a covered benefit)
Plus any one of:
- Cardiovascular Disease
- Dyslipidemia (high LDL, TG, or low HDL)
- Gallstones
- Gynecological abnormalities
- Hypercholesterolemia
- Hypertension
- Metabolic Syndrome
- MAFLD
- Pulmonary Hypoventilation
- Obstructive Sleep Apnea
- Stress Incontinence
- Type 2 Diabetes
- Weight-Bearing Joint Arthropathy
Documentation to bring
- Baseline BMI and weight documentation
- Height documentation
- Documentation of current enrollment in qualified comprehensive weight management program for ≥3 consecutive months
- Proof of current and prior participation in comprehensive weight management program (receipt or certificate and dietary/exercise logs)
- Documentation of trial and failure of Foundayo OR documented contraindication to Foundayo
- Progress notes documenting clinical status at time drug was originally initiated (weight, height, BMI, comorbid conditions)
Quantity limits
- 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 2 mL (4 pens) per 28 days; Maximum 14 twenty-eight-day supplies OR 5 eighty-four-day supplies per 365 days; first 6 fills for new starts limited to 28-day supply or less; 2.5mg strength limited to 2mL per 365 days (titration only, not for chronic use beyond initial 4-week titration period) (84-day)
Approval and renewal
- Initial approval: 7 months
- Renewal: every 6 months
- To renew, the plan looks for at least 5% weight loss from the starting weight, At initial recertification (7 months): physician-verified weight loss of ≥5% of initial weight. For ongoing 6-month recertifications: must have maintained ≥5% weight loss OR continued to lose weight; current BMI must not be less than 18.5 kg/m². Patient must be utilizing maintenance dose (5mg, 7.5mg, 10mg, 12.5mg, or 15mg). For patients unable to tolerate approved maintenance doses, minimum of 5mg once weekly will be covered. Continued comprehensive weight management program enrollment required, at least 17 weeks on therapy before the first renewal, and staying on a maintenance dose of at least 5 mg. Make sure your starting weight and date are in the chart now — renewal is measured against it.
Not covered when
- Zepbound vials and Kwikpens are not a covered benefit (patients may obtain through LillyDirect access program)
- Non-FDA approved diagnoses not covered
- Combination with other GIP and/or GLP-1 receptor agonists not approved (Exenatide, Victoza, Ozempic, Rybelsus, Trulicity, Mounjaro)
- Combination with any other weight loss drugs (Rx, OTC, or herbal) not approved
- 2.5mg strength limited to initial 4-week titration only — not covered for chronic use
- Organic causes of obesity (e.g., hypothyroidism) must be excluded before prescribing
- Demonstration of failed efficacy (not meeting continuation criteria) precludes future coverage of same drug
Exceptions
- New York: All utilization management requirements compliant with applicable New York State insurance laws and regulations
Policy note: BMI thresholds may be adjusted for Asian population on case-by-case basis (BMI ≥25 kg/m² suggests clinical obesity). Documentation must reflect clinical status at time drug was originally initiated. Patients not treated in past 4 months considered new to therapy. OSA indication is integrated into existing weight management criteria (see OSA entry). Annual GLP-1 day-supply limits apply cumulatively across all products. Off-label use (e.g., pre-diabetes extension of SURMOUNT-1) subject to weight management criteria if efficacy is not independent of weight loss.
verified June 5, 2026 · source: weight-management-policy-pdf